Avalo Therapeutics, Inc. (AVTX) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Avalo Therapeutics, Inc. (AVTX) Bundle
Gain a deeper understanding of your Avalo Therapeutics, Inc. (AVTX) valuation analysis using our state-of-the-art DCF Calculator! This Excel template comes preloaded with real AVTX data, enabling you to adjust forecasts and assumptions to accurately calculate the intrinsic value of Avalo Therapeutics, Inc. (AVTX).
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 6.8 | 6.7 | 5.4 | 18.1 | 1.9 | 1.9 | 1.8 | 1.8 | 1.7 | 1.7 |
Revenue Growth, % | 0 | -0.75556 | -19.42 | 234.4 | -89.34 | -2.38 | -2.38 | -2.38 | -2.38 | -2.38 |
EBITDA | -17.4 | -45.5 | -80.5 | -37.3 | -28.0 | -1.9 | -1.8 | -1.8 | -1.7 | -1.7 |
EBITDA, % | -257.2 | -678.47 | -1491.24 | -206.6 | -1452.96 | -100 | -100 | -100 | -100 | -100 |
Depreciation | 1.5 | 1.8 | 1.7 | .2 | .2 | .3 | .3 | .3 | .3 | .3 |
Depreciation, % | 21.61 | 27.51 | 30.7 | 0.91962 | 8.21 | 17.79 | 17.79 | 17.79 | 17.79 | 17.79 |
EBIT | -18.8 | -47.3 | -82.2 | -37.5 | -28.1 | -1.9 | -1.8 | -1.8 | -1.7 | -1.7 |
EBIT, % | -278.81 | -705.99 | -1521.93 | -207.52 | -1461.17 | -100 | -100 | -100 | -100 | -100 |
Total Cash | 11.2 | 18.9 | 54.6 | 13.2 | 7.4 | 1.8 | 1.7 | 1.7 | 1.7 | 1.6 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | 2.2 | 4.8 | 1.9 | .1 | .5 | .5 | .5 | .5 | .5 |
Account Receivables, % | 0 | 32.5 | 88.9 | 10.63 | 7.07 | 27.82 | 27.82 | 27.82 | 27.82 | 27.82 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 0.31111 | 0.0447828 | 0.70396 | 0.1108 | 0 | 0.23413 | 0.23413 | 0.23413 | 0.23413 | 0.23413 |
Accounts Payable | 2.1 | 2.6 | 3.4 | 2.9 | .4 | .6 | .6 | .6 | .6 | .6 |
Accounts Payable, % | 30.79 | 38.42 | 62.41 | 15.97 | 23.18 | 34.15 | 34.15 | 34.15 | 34.15 | 34.15 |
Capital Expenditure | -.3 | -.1 | -.1 | -.1 | -.2 | -.1 | -.1 | -.1 | -.1 | -.1 |
Capital Expenditure, % | -3.88 | -0.93535 | -2.09 | -0.52629 | -8.21 | -3.13 | -3.13 | -3.13 | -3.13 | -3.13 |
Tax Rate, % | -0.04440216 | -0.04440216 | -0.04440216 | -0.04440216 | -0.04440216 | -0.04440216 | -0.04440216 | -0.04440216 | -0.04440216 | -0.04440216 |
EBITAT | -19.1 | -45.3 | -82.0 | -37.5 | -28.1 | -1.9 | -1.8 | -1.8 | -1.7 | -1.7 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -15.9 | -45.2 | -82.3 | -35.0 | -28.8 | -1.8 | -1.6 | -1.5 | -1.5 | -1.4 |
WACC, % | 127.45 | 122.46 | 127.17 | 127.45 | 127.45 | 126.4 | 126.4 | 126.4 | 126.4 | 126.4 |
PV UFCF | ||||||||||
SUM PV UFCF | -1.3 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -1 | |||||||||
Terminal Value | -1 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -1 | |||||||||
Net Debt | -7 | |||||||||
Equity Value | 6 | |||||||||
Diluted Shares Outstanding, MM | 0 | |||||||||
Equity Value Per Share | 20.01 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Avalo Therapeutics’ financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing projections, validating strategies, and enhancing efficiency.
Key Features
- Customizable Research Parameters: Adjust essential inputs like pipeline progress, market potential, and R&D investments.
- Instant Valuation Metrics: Generates intrinsic value, NPV, and other financial outputs on demand.
- High-Precision Analytics: Leverages Avalo Therapeutics' real-world data for accurate valuation results.
- Streamlined Scenario Testing: Easily evaluate various hypotheses and analyze outcomes side by side.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Avalo Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Avalo Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Avalo Therapeutics, Inc. (AVTX)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Proven Expertise: A team of experienced professionals dedicated to advancing biopharmaceuticals.
- Robust Pipeline: A diverse range of product candidates targeting various diseases.
- Commitment to Quality: Adherence to stringent regulatory standards ensures safety and efficacy.
- Collaborative Approach: Partnerships with leading organizations to enhance research and development.
Who Should Use This Product?
- Investors: Evaluate Avalo Therapeutics’ valuation before making stock transactions.
- CFOs and Financial Analysts: Optimize valuation workflows and assess financial forecasts.
- Startup Founders: Understand the valuation methods applied to biotech companies like Avalo Therapeutics.
- Consultants: Provide comprehensive valuation analyses for clients in the biotech sector.
- Students and Educators: Utilize current data to learn and teach valuation practices in a real-world context.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Avalo Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Avalo Therapeutics, Inc. (AVTX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.